Melanoma risk linked with IVF treatment and birth

Science Network, Western Australia, December 3, 2013

An observational study has found a link between melanoma and IVF treatment and birth that may be due to the increased hormone environment necessary for successful birth to those with fertility difficulties.

“Melanin-producing cells are known to be hormonally-responsive and the link between reproductive hormones and melanoma has been studied since the 1970s.

The incidence rate of melanoma increases with age in men and women, but it slows down in women following menopause.”

Link

Leave a comment

Filed under General Research

Huntingdon man who lost half his face to cancer shares his remarkable story

Cambridge News, December 1, 2013

This patient story describes the impact of ocular melanoma (of the eye) and how this man survived. Inspiring and if you wish, contribute to his fundraising for research and treatment.

Link

Leave a comment

Filed under Patient Stories

PCa Raises Melanoma Risk

Renal and Urology News, December1, 2013

Researchers at Tianjin Medical University Cancer Institute and Hospital in Tianjin, China report that men diagnosed with prostate cancer may have up to an 89% increased risk of melanoma. Their findings resulted from a retrospective analysis of two health studies. They did not find a connection to other skin cancers.

Link

Leave a comment

Filed under General Research

RPCI researchers discover novel mechanism of tumor cell invasion in melanoma

Niagara-Wheatfield Tribune, October 30, 2013

Researchers from Roswell Park Cancer Institute and the University of Michigan, Ann Arbor, have identified a formerly unknown pathway of metastasis in melanoma. They found that cell invasion is controlled by certain proteins. These proteins require a special molecule, nucleotide guanosine triphosphate to function. Regulation of these interactions may offer a treatment for the disease.

Link

 

Leave a comment

Filed under Uncategorized

Four Myths About Melanoma

Accurate knowledge is key for prevention, detection and also treatment

Sacramento Bee, October 30, 2013

Read this article for insight into these myths:

  1. Dark skin doesn’t burn so those with it won’t get skin cancer.
  2. Putting on sunscreen as soon as one gets to the beach will protect against skin cancer.
  3. Unexposed skin can’t get melanoma and doesn’t need to be checked.
  4. Only people who tan regularly get skin cancer.
     

Get the facts at link

 

 

Leave a comment

Filed under Uncategorized

The Melanoma Research Foundation’s CURE OM Initiative Announces New Research Grant Recipients and Celebrates Two-Year Anniversary

Sacramento Bee, October 31, 2013

CURE OM (Community United for Research and Education of Ocular Melanoma) was launched two years ago, by the Melanoma Research Foundation, to support research into treatment for ocular melanoma. Their initiative acknowledged a form of melanoma seriously lacking effective treatments once it reaches metastasis.

Under this program to date:

  1. MRF has awarded $650,000 to research for ocular melanoma
  2. 2013 CURE OM research grant awardees Dr. William Tansey from Vanderbilt University Medical Center and Dr. Richard Carvajal from Memorial Sloan-Kettering Cancer Center, both of whom will look deeper into the signaling pathways of OM with the goal of understanding better how to target and halt the disease with effective treatments.
  3. 2012 CURE OM award recipients, Dr. Levi Garraway and Dr. John Sondek.
  4. Since 2011, CURE OM has joined forces and forged meaningful partnerships with organizations including the National Cancer Institute, The Cancer Genome Atlas and The Society for Melanoma Research to drive research efforts.
  5. CURE OM has hosted four international scientific meetings and developed an interdisciplinary and international scientific steering committee.
  6. CURE OM has opened new avenues to support, inform, and connect with the OM community.
    (Excerpted)
    Link

Leave a comment

Filed under Uncategorized

NIH – Melanoma Clinical Trials September 2013

Melanoma Clinical Trials – Recruiting Phase
NCT01814046

Adoptive T Cell Therapy for Metastatic Ocular Melanoma

Phase 2
NCT01369888

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

Phase 1|Phase 2
NCT00304460

Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer

Phase 1
NCT01021059

A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer

 Phase 1
NCT01468818

A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotrheraphy Regimen in Metastatic Melanoma

Phase 2
NCT01495572

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Phase 2
NCT01319565

Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI

Phase 2
1NCT01313429

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

Phase 1
NCT01585415

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

Phase 1
NCT01341496

Tumor Cell Vaccines and ISCOMATRIX(Trademark) With Chemotherapy After Tumor Removal

Phase 1
NCT01336985

Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads

Phase 1
NCT00670748

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Phase 2
NCT01218867

Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes

Phase 1|Phase 2
NCT00720785

Natural Killer Cells and Bortezomib to Treat Cancer

Phase 1

Leave a comment

Filed under Uncategorized